[go: up one dir, main page]

PE20151891A1 - FORMULACION DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca) - Google Patents

FORMULACION DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca)

Info

Publication number
PE20151891A1
PE20151891A1 PE2015002018A PE2015002018A PE20151891A1 PE 20151891 A1 PE20151891 A1 PE 20151891A1 PE 2015002018 A PE2015002018 A PE 2015002018A PE 2015002018 A PE2015002018 A PE 2015002018A PE 20151891 A1 PE20151891 A1 PE 20151891A1
Authority
PE
Peru
Prior art keywords
methyltetrahydropholate
mthf
formulation
calcium amorphous
methylfolate
Prior art date
Application number
PE2015002018A
Other languages
English (en)
Inventor
Herrero Gonzalo Hernandez
Celestino Ronchi
Del Consuelo Isabel C Diaz
Original Assignee
Chemo Res S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48045387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151891(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chemo Res S L filed Critical Chemo Res S L
Publication of PE20151891A1 publication Critical patent/PE20151891A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere a una forma farmaceutica que comprende L-5-metilfolato de calcio amorfo y cisteina como agente estabilizante y opcionalmente, agentes auxiliares adicionales. Las formas farmaceuticas segun la invencion resuelven el problema de la inestabilidad del L-5-metilfolato de calcio amorfo a la oxidacion por aire
PE2015002018A 2013-03-22 2014-03-13 FORMULACION DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca) PE20151891A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13382106.6A EP2781214A1 (en) 2013-03-22 2013-03-22 Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca)

Publications (1)

Publication Number Publication Date
PE20151891A1 true PE20151891A1 (es) 2015-12-20

Family

ID=48045387

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015002018A PE20151891A1 (es) 2013-03-22 2014-03-13 FORMULACION DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca)

Country Status (10)

Country Link
US (1) US20160045440A1 (es)
EP (2) EP2781214A1 (es)
AR (1) AR095691A1 (es)
BR (1) BR112015024351A2 (es)
CA (1) CA2907746A1 (es)
CL (1) CL2015002817A1 (es)
MX (1) MX2015013535A (es)
PE (1) PE20151891A1 (es)
RU (1) RU2015139983A (es)
WO (1) WO2014146975A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170047394A (ko) * 2014-09-04 2017-05-04 리안윤강 진강 해신 파머수티컬 코. 엘티디. (6s)-5-메틸테트라히드로폴산 또는 그 염의 조성물 및 그 제조와 용도
US10406159B2 (en) 2015-01-27 2019-09-10 La Vita Compounding Pharmacy Stable 5-methyltetrahydrofolate formulations to moderate methylenetetrahydrofolate reductase associated polymorphisms
JP2019526612A (ja) 2016-09-12 2019-09-19 スティーブン・ホフマン 認知症を治療するための組成物
CN109164182B (zh) * 2018-09-19 2021-06-11 无锡紫杉药业有限公司 一种对l-四氢叶酸对甲苯磺酸盐（6s）光学纯度的分析检测方法
EP3666260A1 (en) 2018-12-13 2020-06-17 Laboratorios Leon Farma SA Ethinyl estradiol-beta-cyclodextrin complex and process for preparing thereof
CN115605188A (zh) 2020-05-15 2023-01-13 阿尔法西格玛有限公司（It） 包含甲基叶酸的组合物
CN113403355B (zh) * 2021-06-17 2022-05-31 山东大学 一种生物法生产l-5-甲基四氢叶酸的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223500A (en) * 1977-02-22 1993-06-29 Bioresearch S.P.A. Stable pharmaceutical composition of alkaline or alkaline earth 5-methyl tetrahydrofolate
US5124452A (en) * 1978-07-10 1992-06-23 Bioresearch S.P.A. Process for producing d,1-5-methyltetrahydrofolic acid and its salts
CH693905A5 (de) 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
CN101489563A (zh) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
CH698729B1 (de) 2007-05-30 2009-10-15 Cerbios Pharma Sa Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure.
CN102813656B (zh) * 2012-09-13 2014-05-07 广东岭南制药有限公司 5-甲基四氢叶酸或其盐的稳定药物组合物

Also Published As

Publication number Publication date
MX2015013535A (es) 2016-05-31
EP2976066A1 (en) 2016-01-27
CL2015002817A1 (es) 2016-03-11
US20160045440A1 (en) 2016-02-18
CA2907746A1 (en) 2014-09-25
BR112015024351A2 (pt) 2017-07-18
AR095691A1 (es) 2015-11-04
WO2014146975A1 (en) 2014-09-25
RU2015139983A (ru) 2017-04-25
EP2781214A1 (en) 2014-09-24

Similar Documents

Publication Publication Date Title
PE20151891A1 (es) FORMULACION DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca)
CO2017008079A2 (es) Composiciones para el cuidado bucal y métodos de uso
CO2017010894A2 (es) Cuerpo mixto novedoso de compuesto de hierro y óxido de grafeno
ECSP17073965A (es) Derivados de ciclohexano sustituido con amido
GT201500062S (es) Modelo industrial de instrumento para el cuidado oral
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
CL2015002335A1 (es) Derivados de 2-aminopirimidina para el tratamiento de infecciones víricas.
TWD182576S (zh) 面罩架
MX2015010312A (es) Metodos para tratamiento del melanoma.
PE20160052A1 (es) Composicion farmaceutica de clorhidrato de s-cetamina
ME03323B (me) Paraziticidne oralne veterinarske kompozicije koje sadrže sistemski djelujuća aktivna sredstva, metodi i primjene istih
CO2018000350A2 (es) Forma cristalina de la plinabulina monohidratada, composiciones que la comprenden y procedimientos de elaboración
TWD157919S (zh) 香水瓶
CR20160044S (es) Dispensador de jabon
CR20150440A (es) Nuevos derivados de piridina
GT201500247A (es) Imidazopiridazinas sustituidas
AR093645A1 (es) Una formulacion estabilizada de pemetrexed
MX2019002781A (es) Estabilizadores de mastocitos para el tratamiento de hipercitoquinemia e infeccion viral.
UY35848A (es) Tienopirimidinas
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
NI201600006A (es) Pirazolo-piridinaminas sustituidas
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
CR20160448A (es) Nuevos derivados de piridina
CO2017007316A2 (es) Formulación farmacéutica

Legal Events

Date Code Title Description
FD Application declared void or lapsed